Xu Z H, Shimakura K, Yamamoto T, Wang L M, Mineshita S
Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, Japan.
Jpn J Pharmacol. 1998 Jan;76(1):51-6. doi: 10.1254/jjp.76.51.
This study was performed to demonstrate an experimental procedure of pulmonary edema induced by angiotensin I (AT I) in rats and to elucidate the mechanism of hemodynamic pulmonary edema. In the previous pilot study, 20 microg/kg of AT I was found to be an adequate dose for inducing pulmonary edema. To elucidate the mechanism of AT I pulmonary edema and protective measures against it, we observed the effects of captopril (CAP, 5 and 10 mg/kg), an angiotensin converting enzyme inhibitor; losartan (LOS, 10 mg/kg), an angiotensin II (AT II)-receptor antagonist; and phentolamine (PHE, 10 mg/kg), an alpha-adrenergic receptor blocker, on AT I-induced pulmonary edema in rats. Similarly, we also observed the effects of CAP (10 and 20 mg/kg) on pulmonary edema induced by 25 microg/kg of adrenaline (ADR) in rats. The development of AT I-induced pulmonary edema was significantly suppressed by CAP and LOS, but was unaffected by PHE. In contrast, the development of ADR-induced pulmonary edema was not suppressed by CAP. These results suggest that AT I-induced pulmonary edema is developed via the AT II and a specific AT II-receptor, without the indirect action of adrenaline.
本研究旨在演示大鼠中由血管紧张素I(AT I)诱导的肺水肿的实验过程,并阐明血流动力学性肺水肿的机制。在先前的预试验研究中,发现20微克/千克的AT I是诱导肺水肿的合适剂量。为了阐明AT I性肺水肿的机制及其预防措施,我们观察了血管紧张素转换酶抑制剂卡托普利(CAP,5和10毫克/千克)、血管紧张素II(AT II)受体拮抗剂氯沙坦(LOS,10毫克/千克)和α-肾上腺素能受体阻滞剂酚妥拉明(PHE,10毫克/千克)对大鼠AT I诱导的肺水肿的影响。同样,我们也观察了CAP(10和20毫克/千克)对大鼠25微克/千克肾上腺素(ADR)诱导的肺水肿的影响。CAP和LOS可显著抑制AT I诱导的肺水肿的发展,但PHE对其无影响。相反,CAP不能抑制ADR诱导的肺水肿的发展。这些结果表明,AT I诱导的肺水肿是通过AT II和特定的AT II受体发生的,而不是通过肾上腺素的间接作用。